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Abstract
Introduction Molecular imaging aims towards the non-
invasive characterization of disease-specific molecular
alterations in the living organism in vivo. In that, molecular
imaging opens a new dimension in our understanding of
disease pathogenesis, as it allows the non-invasive deter-
mination of the dynamics of changes on the molecular
level.
Imaging of AD characteristic changes by μPET The
imaging technology being employed includes magnetic
resonance imaging (MRI) and nuclear imaging as well as
optical-based imaging technologies. These imaging modal-
ities are employed together or alone for disease phenotyp-
ing, development of imaging-guided therapeutic strategies
and in basic and translational research.
Summary In this study, we review recent investigations
employing positron emission tomography and MRI for
phenotyping mouse models of Alzheimers’ disease by
imaging. We demonstrate that imaging has an important




Alzheimer’s disease (AD) is the most common neurode-
generative disorder and can only be diagnosed with
certainty by post-mortem examination of brain tissue. The
disease is characterised by extracellular deposition of senile
(amyloid) plaques, intracellular neurofibrillary tangles
(NFT), synaptic loss and neurodegeneration. The amyloid
plaques contain insoluble fibrils of the amyloid-beta (Aβ)
fragment of a larger precursor protein (amyloid precursor
protein [APP]), whereas intracellular NFT consist of
hyperphosphorylated tau protein [1, 2]. Mutations in
presenilin 1 (PS1), presenilin 2 (PS2) and APP genes have
been associated with familial forms of AD and have been
shown to alter normal processing of APP by proteases
(secretases) causing the extracellular accumulation of
amyloid plaques [3–7]. Cross-sectional studies on individ-
uals with AD or elderly controls have contributed to the
current understanding of the disease but are limited by the
fact that analyses can only be performed in post-mortem
brain. Therefore, the advantages of mouse models are as
follows: (1) analysing the disease-specific pathophysiolog-
ical mechanisms, (2) understanding the genetic alterations
or interactions, as well as (3) testing therapeutic interven-
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Münster, Germanytions at definite timepoints. Nowadays, these mouse models
of AD are typically transgenic (tg) mice carrying mutations
in the APP, PS1 or PS2 gene. Several tg mouse models
have been generated, which are reviewed by Higgins and
Jacobsen [8]. Some of them, e.g., the tg mouse models
Tg2576 or APP23 overexpress the human APP (hAPP) in
combination with distinct mutations like the ‘Swedish’ mu-
tation (APPK670N, M671L [9, 10]) or in case of the PDAPP
mouse model the ‘London’ mutation (APPV717F [11]).
Others like the PS1 M146L or M146V model express
mutant PS1 [12] or, by crossing, the tg animals create
double-tg mice (PS1/APP), carrying two of these mutations
in the mouse genome [13]. Except for the PS1 model, these
murine models of AD typically express sufficiently high
levels of hAPP and Aβ to insure amyloid deposition.
Besides being useful tools in the analysis, understanding
and possible treatment of the disease based on findings in
histology, biochemistry, molecular biology and behavioural
testing, these mouse models have been of help in character-
isation of amyloid-imaging agents and have been used for
non-invasive phenotyping by multi-tracer positron emission
tomography (PET).
PET-based imaging in AD
PET allows non-invasive assessment of physiological,
metabolic and molecular processes in humans and animals
in vivo. With the achievements in detector technology,
spatial resolution of PET has been considerably improved
(1–2 mm), enabling for the first time investigations in small
experimental animals such as mice. With the developments
in radiochemistry and tracer technology, a variety of en-
dogenously expressed and exogenously introduced genes
can be analysed by PET. This opens up the exciting and
rapidly evolving field of molecular imaging, aiming
towards the noninvasive localisation of a biological process
of interest in normal and diseased cells, both in animal
models and humans in vivo. The main and most intriguing
advantage of molecular imaging is the kinetic analysis of a
given molecular event in the same experimental subject over
time. This will allow non-invasive characterisation and
“phenotyping” of animal models of human disease at various
disease stages, under certain pathophysiological stimuli or
after therapeutic intervention, respectively.
PET allows the quantitative localisation of expression of
genes coding for membrane receptors and transporters or
cellular enzymes. By measuring (a) the binding of the
respective receptor ligand, (b) the transport of a specific
compound or (c) the accumulation of the specific enzyme
substrate, quantitative analysis can be performed. Important
endogenous enzymes and receptors in the field of neuro-
degeneration, with special focus on AD, which are non-
invasively assessed already on a routine basis in the clinical
application by specific probes and PET are:












These tracers are clinically applied for early detection
of AD ([
18F]FDG, [
11C]MP4A) and in the assessment of
neuronal integrity after stroke ([
11C]FMZ, [
18F]FDG) [14,
15]. The overall attractive goal in neuroscience research is
that, with the advent of μPET, these tracers can be applied
in animal models for AD for non-invasive phenotyping of
these models as well as in the development of experi-
mental therapeutics, such as growth factor administration,
gene therapy and cell transplantation. Animal PET will
serve as a platform to test these therapies in a relatively
efficient manner, allowing a more rapid progression from
pre-clinical to clinical studies. Most importantly, the same
in vivo imaging parameters can be used pre-clinically and
clinically, enabling a direct comparison when translating
experimental molecular imaging markers into clinical
application.
To date, the cerebral glucose metabolism as measured by
[
18F]FDG-PET is a sensitive non-invasive surrogate marker
for the diagnosis of AD [16, 17]. Typically, [
18F]FDG-PET
shows reduced glucose metabolism in posterior cingulate,
temporoparietal and prefrontal association cortex with
preservation of primary sensorimotor cortex and basal
ganglia. The largest reduction is found in the posterior
cingulate cortex [18], and this metabolic alteration becomes
even apparent before the onset of cognitive impairment in
persons at genetic risk for AD [19]. Even very mild
probable AD patients (defined by Mini Mental Score
greater than 24) can be diagnosed with a 84% sensitivity
and 93% specificity [16]. Moreover, degeneration of
cholinergic neurons located in basal ganglia, particular in
the nucleus basalis of Meynert and subsequent alteration of
cortical acetylcholine esterase activity is one of the central
features in AD and Lewy body dementia, which can be
assessed by [
11C]MP4A-PET. After passing the blood–brain
barrier, [
11C]MP4A is hydrolysed by AChE and trapped
within the brain proportional to regional AChE activity
[20]. Currently, the value of [
11C]MP4A-PET is being
investigated in the differential diagnosis of AD from other
forms of dementia [21–24]. [
11C]FMZ binds to central
benzodiazepine receptors, and, as measured by PET, it is an
early indicator of preserved cortical neuronal integrity [15].
[
18F]FDG together with [
11C]FMZ was shown to be also
helpful in the diagnosis of other forms of dementia
including variants of Creutzfeld–Jakob disease [25].




reveal direct molecular information on glucose metabolism,
AChE activity and binding to benzodiazepine receptors,
they can only serve as surrogate markers for cellular density
or neuronal integrity and thus as indirect surrogate
measures of presence and progression of AD. Therefore, a
further imaging marker that permits direct detection of the
disease process, such as neurofibrillary tangles or Aβ
plaques in vivo, would be very helpful. Direct imaging of
these neuropathological changes would improve early
diagnostic certainty of the disease, rather than waiting until
behavioural manifestations can be detected. Most impor-
tantly, repetitive imaging of senile plaques in combination
with glucose and acetylcholine metabolism as surrogate
markers would provide a readout of the efficacy of
experimental therapeutics aimed at removing these neuro-
pathologic lesions. So far, invasive direct imaging of Aβ
plaques has been developed by using fluorescein-labelled
Aβ,a n t i - A β antibodies and fluorescent derivatives of
thioflavin T and Congo red as specific targeting agents and
multiphoton microscopy in live tg mice [26–28]. Although
multiphoton microscopy requires craniotomy, these studies
indicated that exogenous fluorescent targeting agents bind
to existing plaques in vivo if delivery to the brain is
sufficient. Intriguingly, this imaging method has been
successfully used to follow plaque-directed immunotherapy
in the same experimental animal over time [26].
Direct AD plaque imaging by PET
Based on findings with the amyloid-binding compound
thioflavin, neutral benzothiazoles were further modified and
investigated as potential PET agents. Klunk et al. [29]




11C]6-OH-BTA-1) also named “Pittsburgh Com-
pound B” ([
11C]PIB) and could demonstrate two- to
threefold higher retention of the radio-labelled compound
in areas of association cortex in patients with AD as
compared to healthy controls. An Aβ-binding compound,
which can be radio-labelled by
18F, has also been developed.
2-(1-(6-[(2-[
18F]fluoroethyl)(methyl)amino]-2-naphthyl)eth-
ylidene)malononitrile labelled senile plaques in tissue
sections from AD brain; however, its in vivo specificity is
not clarified yet due to its low clearance from white matter
[30, 31].
Direct imaging of Aβ plaques in tg mouse models has
been performed using the PIB compound. Toyama et al.
[32] used the Tg2576 mouse model of AD to evaluate the
feasibility of μPET imaging using the radio-labelled com-
pound [
11C]6-OH-BTA-1 to image and quantify Aβ
plaques in vivo. Interestingly, they found excellent brain
uptake of radioactivity in tg and wild-type mice but no
specific binding of the labelled compound to Aβ plaques in
tg animals compared with the wild type, although histo-
chemical staining with thioflavin S showed numerous Aβ
plaque deposits in the tg animals but not in the wild type.
Similar findings have been reported by Klunk et al. [33, 34]
in PIB μPET studies using the PS1/APP mouse model. To
further consolidate these findings and to compare the
differences in binding of PIB in human versus tg mouse
brain, they performed in vivo, ex vivo and post-mortem in
vitro studies with brain tissue from PS1/APP tg mice [34].
Similar to the Tg2576 murine model, PS1/APP mice
showed extensive plaque staining [34, 35], but no signif-
icant difference in the retention of [
11C]PIB. Ex vivo
studies (with increased sensitivity as compared to in vivo
μPET) analysing the binding capacity of [
11C]PIB in brains
of 15-month-old PS1/APP mice did not show any signif-
icant difference either. Comparison of in vitro [
3H]PIB
binding to human AD brain as well as PS1/APP brain
demonstrated a high affinity [
3H]PIB-binding site in AD
brains but not in PS1/APP mouse brain. The Bmax for
binding of [
3H]PIB to PS1/APP brain was more than 1,000-
fold lower than the Bmax for binding of [
3H]PIB to AD
brain. A possible explanation for this suggests that there is
low efficiency for forming high affinity PIB-binding sites
during plaque deposition in tg mice, which may be due to
differences in the time course of Aβ deposition or the
presence of tissue-specific factors during deposit formation.
Imaging of AD characteristic changes by μPET
Besides the direct measurement of Aβ plaques, μPET
imaging can help in the characterisation and phenotyping of
animal models of AD by taking advantage of radiotracers
already implemented in the clinical application for diagno-




As already pointed out, non-invasive small animal PET
imaging allows the assessment of AD imaging parameters
at definite times and this repetitively over time within the
same animal. In a knock-out mouse model for the brain/
neuron-specific insulin receptor (NIRKO), Schubert et al.
[36] investigated the influence of neuronal insulin resis-
tance in neurodegeneration and could demonstrate reduced
Akt and GSK3β phosphorylation and hyperphosphoryla-
tion of tau protein in NIRKO mice as compared to controls.
Speculations on the regulative role of neuronal insulin
receptors on cerebral glucose metabolism led to the
performance of μPET analyses with NIRKO mice in vivo
with [
18F]FDG in collaboration with our group. In this
study, tg and control animals underwent [
18F]FDG-PET as
well as in vivo high-resolution μMRI for co-registration
aspects to differentiate distinct brain regions and hypermet-
Eur J Nucl Med Mol Imaging (2008) 35 (Suppl 1):S107–S113 S109abolic active harderian glands and to ensure proper region-
of-interest analysis. Brain-to-background ratios for [
18F]
FDG uptake in NIRKO mice did not show any significant
difference as compared to control animals (Fig. 1) suggest-
ing that, in this specific study, insulin signalling did not
have a substantial influence on basal brain glucose
metabolism detectable by μPET.
A subsequent study included multi-tracer PET imaging
in an AD mouse model in collaboration with Heneka et al.
[37]. Using APP23 tg mice, Heneka et al. [37] investigated
the effect of locus ceruleus (LC) degeneration [by induction
with N-(2-chloroethyl)-N-ethyl-bromo-benzylamine (dsp4)]
and its contribution to AD pathogenesis. Biochemical and
histological findings demonstrated loss of LC neurons,
Fig. 1 Unaltered spatial learning, long-term memory and brain
glucose metabolism in NIRKO mice. a Escape latency to find the
platform after exposure to the water maze for 7-week-old control
(open circles) and NIRKO (filled circles) mice. Data presented per
session represent the mean of four trials per session and the mean of
seven animals of each genotype±SEM. b Escape latency to find the
platform after exposure to the water maze for 11-month-old control
(circles) and NIRKO (triangles) mice. Data are separated for mice
having performed a Morris water maze task at the age of 7 weeks
(experienced mice, open symbols) and those that have not before
encountered a Morris water maze task (naive mice, filled symbols).
Data presented per session represent the mean of four trials per session
and the mean of four to seven animals of each genotype±SEM.
c. Shown are representative high-resolution MRI (upper)a n d
matched [
18F]FDG-μPET images (lower) through the brain of a
representative control mouse (upper) and a representative NIRKO
mouse (lower)[ t r a n s a x i a l( left), coronal (center), and sagittal
(right)]. ROI were placed in a transaxial plane (arrow). Distinction
between brain and hypermetabolic harderian glands (arrowhead)i s
made by co-registration with MRI (from Schubert et al. [36] with
permission, copyright 2004 by the National Academy of Science)
S110 Eur J Nucl Med Mol Imaging (2008) 35 (Suppl 1):S107–S113depletion of noradrenaline (NA), increase in microglial and
astroglial activation and an increase in amyloid plaques in
specific brain regions after dsp4 treatment. The loss of NA
was also associated with increased cognitive deficits in
APP23 tg animals. To investigate the effect of LC
degeneration in this mouse model, we performed multi-
tracer μPET imaging assessing cerebral glucose metabo-
lism, acetylcholine esterase activity and FMZ binding. For





FMZ-PET. The different sets compared (1) non-treated
APP23 with wild-type mice at 10 and 13 months of age,
(2) dsp4- and control-treated tg as well as wild-type mice
4 weeks after treatment and (3) APP23 tg mice with and
without dsp4-treatment 4 and 12 weeks after dsp4-applica-
tion. The results showed no significant differences in the
non-treated APP23 tg versus wild-type animals at baseline or
after aging. Most importantly, tg mice receiving the dsp4-
treatment differed significantly from non-treated tg animals
4 weeks after the treatment in FMZ binding and acetylcho-
line esterase activity. Moreover, 12 weeks after LC degen-




11C]FMZ) could be detected
indicating that LC degeneration and inflammatory reaction
contributes significantly to AD pathogenesis (Fig. 2).
Summary
Our results demonstrate the usefulness of radiotracers
originally applied to show a characteristic pattern of altered
brain glucose metabolism, acetylcholine esterase activity or
neuronal integrity in patients with AD, also in multi-modal
μPET imaging for characterisation and non-invasive phe-
notyping of mouse models of AD. However, it should be
pointed out that μPET imaging in mice still has major
limitations with regards to spatial resolution of currently
available μPET scanners, attenuation correction and correct
quantification, as well as anesthesia-induced changes of
radiotracer uptake. These technical considerations have to
Fig. 2 Altered cerebral glucose metabolism, neuronal integrity and
cholinergic function detected in vivo after noradrenergic depletion of





images (second–fourth rows, coronar is left;t r a n s a x i a l ,middle;
sagittal, right) through the brain of saline-treated (left panel) and




11C]MP4A uptake in saline-treated wild-type (wt-con) and
saline-treated APP23 (tg-con) mice at 13 months of age. No significant




11C]MP4A uptake in saline-injected (tg-con) and dsp4-treated (tg-dsp4)
APP23 tg mice at the same age revealed a decrease in all parameters
after LC degeneration (mean±SEM; n=4 animals per group; Student’s t
test; *p<0.05; from Heneka et al. [37] with permission, copyright 2006
by the Society for Neuroscience)
Eur J Nucl Med Mol Imaging (2008) 35 (Suppl 1):S107–S113 S111be taken appropriately into account and further elaborated
to enable μPET-based phenotyping of mouse models of
brain disease as a tool to investigate the dynamics of
disease-specific molecular alterations in vivo.
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